globe
Select a Region Asia Pacific

Asset Strategy

Today’s biggest challenge for pharma is securing an adequate pipeline of innovative products. So, when an asset in development seems promising, it is vital to maximize its value. Choices are expensive and outcomes are uncertain, especially in new areas with competitors racing you to the launch pad. EVERSANA’s consultants help frame the challenge, develop the options and value the asset under different scenarios, leading to clarity of trade-offs and quality decisions.

  • Asset Development Strategy: Definition and evaluation of TPPs under different trial choices, combining decision analysis and financial analysis to trade off risk and return and define the best path forward
  • Asset Commercial Strategy: Positioning, landscape and competitive analysis including, regulatory and pricing uncertainties, to make the most of an in-market asset
  • Asset Valuation: If an asset is the subject of licensing, partnership or outright sale agreements, negotiation support using a valuation methodology incorporating probability and uncertain events to yield a clear value under the full range of scenarios
  • Loss of Exclusivity: If an asset faces generic competition upon LoE, pricing, fighter brand and/or partnership approaches to maintain as much value as possible with a choice between creative approaches that have been rigorously evaluated

We have supported many clients, from smaller to multinational pharma and MedTech companies, across the APAC markets in obtaining the highest value from choosing the right path for their individual assets.


Our Case Studies

Growth Strategy for a Legacy Brand in China

A Japanese pharmaceutical company wished to identify the next level of growth opportunities for its legacy product targeting chemotherapy-induced neutropenia in China. We assessed the market opportunity and competitive dynamics and developed a new growth strategy based on improved positioning.

Business Assessment for an Orphan Drug in the U.S. Oncology Market

A Japanese client was developing an asset for a niche hematology condition, where the drug class was being used off-label. We helped the client to assess the overall business potential of the new drug across various clinical settings under different regulatory and competitive scenarios.

Pre-Launch Assessment

Our client was looking to launch its innovative offering for multiple sclerosis. EVERSANA partners assessed the market landscape, mapping the patient journey, key treatments, unmet needs and valuing the commercial opportunity for their new offering, including price testing.

Competitive Threat Assessment for a Novel Treatment in an Orphan Indication

A Japanese company was developing a novel oral treatment for a rare indication in hematology. We assessed the threat posed by a competitor drug in the same class but with a different clinical profile and recommended a strategy to emphasize core aspects of the value proposition.

Find out how we can take your business to the next level.